[HTML][HTML] PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer cell, 2015 - cell.com
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer Cell, 2015 - infona.pl
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou, L Friboulet, DP Kodack, LD Engstrom… - Cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
[HTML][HTML] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer Cell, 2015 - cell.com
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
[HTML][HTML] PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer cell, 2015 - ncbi.nlm.nih.gov
We report the preclinical evaluation of PF-06463922, a potent and brain penetrant
ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 …
[HTML][HTML] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer Cell, 2015 - Elsevier
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer Cell, 2015 - europepmc.org
We report the preclinical evaluation of PF-06463922, a potent and brain penetrant
ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 …
[PDF][PDF] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou - 2017 - pdfs.semanticscholar.org
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15- oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h]
[2,5,11]-b Page 1 Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] …
[2,5,11]-b Page 1 Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] …
[PDF][PDF] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li… - Cancer Cell, 2015 - core.ac.uk
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …
[PDF][PDF] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
HY Zou - 2017 - academia.edu
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15- oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h]
[2,5,11]-b Page 1 Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] …
[2,5,11]-b Page 1 Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] …